|
Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study Clinical research trials and Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study. Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study clinical trial. Subjects often receive the most expert healthcare possible for their Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study  Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
For Condition: Ankylosing Spondylitis
Status: Recruiting
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ,
Synopsis: This study will explore how genes may influence the severity of ankylosing spondylitis, a form of arthritis that affects the spine. Patients have inflammation of the joints of the spine, which may cause the bones of the spine to fuse, resulting in difficulty performing daily activities. Patients who developed ankylosing spondylitis after age 16 and have had the disease for less than 20 years may be eligible for this study. The onset of disease is dated to the first appearance of symptoms of inflammatory low back pain or restricted spinal motion. Patients with a spondyloarthropathy other than AS may not participate. Candidates will be screened with a medical history and physical examination, blood test, and review of their medical records. They will also complete a questionnaire about their disease symptoms and medical history. Those enrolled in the study will return to the NIH Clinical Center at 2, 6, 10, 14, 18, 22, and 26 months after screening for examination of the joints, measurement of flexibility of the spine, and a blood test. They will also complete a symptoms assessment questionnaire. At the first study visit (2 months after screening), x-rays will be taken of the pelvis, lower back, and neck, if recent X-rays (within 1 year) are not available. These x-ray studies will be repeated on all patients at their last visit (26 months after screening).
Details: The susceptibility to ankylosing spondylitis (AS) is largely genetically determined. Recent studies suggest that the severity of AS is also influenced by genetic factors. The goal of this study is to identify genes that influence the severity of AS. We hypothesize that genetic markers of susceptibility, including human leukocyte antigen (HLA) polymorphisms, and genes that regulate inflammation and bone formation, influence the severity of AS. In this prospective longitudinal study, we will test the association of several genetic markers with the severity of AS in 200 patients. Each patient will have had AS for less than 20 years. Measures of AS severity will be patient-reported pain and stiffness, functional disability, patient and physician global assessments, joint counts, number of tender entheses, spinal mobility, and laboratory measures of inflammation. These measures will be assessed every 4 months for 2 years. We will also evaluate new laboratory tests as measures of the activity of AS. Identifying genetic markers that are associated with differences in the severity of active inflammation in AS will enhance our understanding of the pathogenesis of this disease by suggesting mechanisms and pathways involved in the development of long-term damage. In a separate but related protocol, we will assess genetic markers associated with spinal fusion and long-term functional disability in patients with AS.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Participants will: 1. have been diagnosed with AS by the modified New York criteria. 2. have had AS for less than 20 years. The duration of AS will be dated from the time of onset of symptoms of inflammatory low back pain or restricted spinal motion. 3. be able to read English. EXCLUSION CRITERIA: Potential participants will be excluded if: 1. onset of AS was at age 16 or younger. 2. have a spondyloarthropathy other than AS. 3. are unable to provide informed consent. 4. anticipate not being available or able to comply with the schedule of study visits. Children will necessarily be excluded.
Total Enrollment: 50
Location and Contact Information:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 030131; 03-AR-0131
Study Start Date: March 17, 2003
Record last reviewed: February 19, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00056719
Other Ankylosing Spondylitis Studies:
1. Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
2. Genetic Determinants of Ankylosing Spondylitis Severity
3. Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis
4. Genetics of Ankylosing Spondylitis
5. Prevention of Arthritis-Related Work Disability
Related Studies:
Other Ankylosing Spondylitis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
|
|
|
|
|
|
|
|
